Diabetic Nephropathy Clinical Trials | A Drug Pipeline Analysis Report 2024 | Bayer, Novartis, Boehringer Ingelheim, CSL Behring

DelveInsight's 'Diabetic Nephropathy Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Nephropathy pipeline domain.
Download sample pages of our latest Diabetic Nephropathy Pipeline Report @ https://www.delveinsight.com/report-store/diabetic-nephropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Diabetic Nephropathy Pipeline Report
Over 34+ Diabetic Nephropathy pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Nephropathy market would significantly increase market revenue.
Leading Diabetic Nephropathy companies developing novel drug candidates to improve the Diabetic Nephropathy treatment landscape include Bayer, Novartis, Boehringer Ingelheim, CSL Behring, and others.
Promising Diabetic Nephropathy pipeline therapies in various stages of development include Finerenone, Nidufexor (LMB763), BI 685509, CSL346, and others.
Diabetic Nephropathy Overview
Diabetic nephropathy, also known as diabetic kidney disease (DKD), is a serious complication of diabetes mellitus characterized by damage to the kidneys' filtering units (glomeruli) due to long-term diabetes and elevated blood sugar levels. Here's an overview covering its causes, signs and symptoms, diagnosis, and treatment options:

Diabetic Nephropathy Causes:
The primary cause of diabetic nephropathy is prolonged exposure to high blood sugar levels (hyperglycemia) associated with diabetes mellitus. Other contributing factors include:

1. Glomerular hypertension and hyperfiltration: High blood sugar damages the small blood vessels (capillaries) in the glomeruli, leading to increased pressure and hyperfiltration in the kidneys.

2. Proteinuria: Over time, damage to the glomeruli results in leakage of proteins (especially albumin) into the urine (proteinuria), which further contributes to kidney damage.

3. Activation of inflammatory and fibrotic pathways: Chronic inflammation and fibrosis in the kidneys accelerate the progression of diabetic nephropathy.

4. Genetic predisposition: Some individuals may have genetic factors that make them more susceptible to diabetic kidney disease.

Diabetic Nephropathy Signs and Symptoms:
In the early stages, diabetic nephropathy may not cause noticeable symptoms. As the condition progresses, signs and symptoms may include:

1. Proteinuria: Excess protein in the urine, detected through urine tests.

2. Edema: Swelling, particularly in the legs, ankles, or around the eyes, due to fluid retention.

3. Hypertension: High blood pressure, often worsening as kidney function declines.

4. Fatigue and weakness: Generalized tiredness and reduced energy levels.

5. Changes in urination: Decreased urine output, increased frequency of urination, especially at night (nocturia), or foamy urine.

Diabetic Nephropathy Diagnosis:
1. Urine Tests:
- Urinalysis: Detects proteinuria, hematuria (blood in urine), and other abnormalities.
- Albumin-to-creatinine ratio (ACR): Measures the amount of albumin in the urine relative to creatinine, indicating kidney damage.

2. Blood Tests:
- Serum creatinine and estimated glomerular filtration rate (eGFR): Measures kidney function. Creatinine levels increase as kidney function declines, and eGFR estimates how well the kidneys are filtering waste products from the blood.
- Blood glucose and hemoglobin A1C: To assess diabetes control.

3. Imaging Studies:
- Ultrasound: To visualize the kidneys and assess their size and structure.

4. Kidney Biopsy: In some cases, a biopsy may be performed to examine a small sample of kidney tissue under a microscope, particularly if the diagnosis is uncertain or if other kidney diseases are suspected.

Diabetic Nephropathy Market Treatment Options:
The management of diabetic nephropathy focuses on slowing its progression, managing complications, and preserving kidney function:

1. Blood Sugar Control: Tight control of blood glucose levels through diet, exercise, and medications (insulin or oral hypoglycemic agents) is essential to prevent further kidney damage.

2. Blood Pressure Management: Controlling hypertension (high blood pressure) with medications such as ACE inhibitors or angiotensin II receptor blockers (ARBs) is crucial. These medications also help reduce proteinuria and protect kidney function.

3. Protein Restriction: Limiting dietary protein intake may be recommended to reduce the workload on the kidneys.

4. Cholesterol Management: Statin medications may be prescribed to manage cholesterol levels and reduce cardiovascular risk.

5. Diuretics: These medications may be used to reduce edema and manage fluid retention.

6. Dialysis and Kidney Transplant: In advanced stages of diabetic nephropathy, dialysis (hemodialysis or peritoneal dialysis) or kidney transplantation may be necessary.

7. Lifestyle Modifications: Adopting a healthy lifestyle with a balanced diet, regular exercise, smoking cessation, and avoiding excessive alcohol consumption can help manage diabetes and reduce the risk of complications.

Diabetic Nephropathy Market Outlook:
The prognosis for diabetic nephropathy varies depending on factors such as the stage of the disease at diagnosis, the effectiveness of treatment, and the presence of other medical conditions. Early detection and management are crucial to slowing progression and preserving kidney function. Regular monitoring by healthcare providers, adherence to treatment recommendations, and lifestyle modifications are essential for optimizing outcomes and reducing the risk of complications associated with diabetic kidney disease.

Download sample report @ https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Nephropathy Pipeline Analysis: Drug Profile
AUP 16: Aurealis Therapeutics
Finerenone (BAY94-8862), a Nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer commenced a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III FIDELIO-DKD study in September 2015 to investigate the safety and efficacy of Finerenone in addition to standard of care in subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease. This trial was completed in April 2020. During the start of 2021, the company announced their New Drug Application (NDA) and granted Priority Review. The findings from the Phase III FIDELIO-DKD study, which were presented in detail at the American Society of Nephrology's (ASN) Kidney Week Reimagined 2020 and subsequently published in the New England Journal of Medicine in October 2020, were used to support this regulatory filing.
Discover more about the emerging Diabetic Nephropathy drugs @ https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Nephropathy Key Companies
Bayer
Novartis
Boehringer Ingelheim
CSL Behring
Diabetic Nephropathy Pipeline Therapies
Finerenone
Nidufexor (LMB763)
BI 685509
CSL346
Diabetic Nephropathy Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Diabetic Nephropathy Pipeline Report
Coverage: Global
Key Diabetic Nephropathy Companies: Aurealis Therapeutics, Charsire Biotechnology Corporation, and others
Key Diabetic Nephropathy Pipeline Therapies: Finerenone, Nidufexor (LMB763), BI 685509, CSL346, and others
Find out more about the Diabetic Nephropathy treatment options in development @ https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report: https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.